Skip to Main Content

Author Details

Javier G??mez
Hospital Universitario Marques de Valdecilla
2003
20
17
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36252599Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.Lancet Respir Med2023
35012962Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.Life Sci Alliance2022
33875457Molecular diagnosis in non-small-cell lung cancer: expert opinion on <i>ALK</i> and <i>ROS1</i> testing.J Clin Pathol2022
34075384Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.medRxiv2021
32224306Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.Lancet Oncol2020
25730906Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.Oncotarget2015
25197016MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.BMC Cancer2014
23117071Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Ann Oncol2013
23397080Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.Med Oncol2013
22484722A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.Cancer Chemother Pharmacol2012
23269338Leydig cell tumour: enucleation as a therapeutic choice in a case with atypical symptoms.Arch Esp Urol2012
20643862Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.Ann Oncol2011
21546066Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.Gynecol Oncol2011
21416137Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Cancer Chemother Pharmacol2011
19417019Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.Clin Cancer Res2009
19652065Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.J Clin Oncol2009
18483378Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.Clin Cancer Res2008
17553201Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.Clin Colorectal Cancer2007
15084621Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.J Clin Oncol2004
12932661Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.Eur J Cancer2003
  • 1 - 20 of 20

Recommended Authors

Corinne Maurice-Dror
Institute of Oncology
Career Start Year 2016
Number of shared co-authors 0
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 0
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 0
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 1
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 0
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 1
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 0
Shane White
Olivia Newton-John Cancer Wellness and Research Centre
Career Start Year 2000
Number of shared co-authors 0
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Isabelle Ray-Coquard
University Claude Bernard Lyon I
Career Start Year 1997
Number of shared co-authors 3
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year 1997
Number of shared co-authors 1
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 0
Nam Bui
Stanford University
Career Start Year 1996
Number of shared co-authors 0
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 1
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Career Start Year 1995
Number of shared co-authors 1
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 1
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 0
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 0
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Career Start Year 1987
Number of shared co-authors 7
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 0
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 1
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 1
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 0
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 2
Ronald de Wit
Erasmus MC Cancer Institute
Career Start Year 1972
Number of shared co-authors 0

Collaborators

Antonio Nieto
Clinical R&D
Co-authored papers 6
Jos?? Jimeno
Promontory Therapeutics Inc.
Co-authored papers 6
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Co-authored papers 3
Bonaventura Clotet
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 2
Noemi Cabello
Centro Sandoval and Hospital Universitario Clinico de San Carlos
Co-authored papers 2
Jos?? Barber??n
Hospital Universitario HM Monteprincipe, HM Hospitales
Co-authored papers 2
Greg J Towers
University College London
Co-authored papers 2
Beatriz de Rivas
University of the Basque Country UPV/EHU
Co-authored papers 2
Pablo Avil??s
Departamento de Toxicologia y Farmacologia Preclinica
Co-authored papers 2
Rubin Lubomirov
Clinical Development
Co-authored papers 2
Kirsten Obernier (CM4AI)
University of California San Francisco
Co-authored papers 2
Nuria Izquierdo-Useros
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 2
Jose F Varona
Hospital Universitario HM Monteprincipe, HM Hospitales
Co-authored papers 2
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Salvador Fudio
Clinical Development
Co-authored papers 2
Soner Yildiz
University of Geneva
Co-authored papers 2
Julio Ancochea
Instituto de Salud Carlos III, Hospital Universitario La Princesa
Co-authored papers 2
Sonia Zu??iga
Campus Universidad Autonoma de Madrid
Co-authored papers 2
Roger Paredes
Hospital Germans Trias i Pujol
Co-authored papers 2
Daniel Carnevali-Ruiz
Hospital Universitario Quironsalud Madrid
Co-authored papers 2
Luis Enjuanes
Campus Universidad Autonoma de Madrid
Co-authored papers 2
Roberto Vates
Hospital Universitario de Getafe
Co-authored papers 2
Lucy Thorne
University College London
Co-authored papers 2
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 2
Daniel Abad
Universidad Europea
Co-authored papers 2
Pedro Landete
Hospital Universitario de La Princesa
Co-authored papers 2
Maria J S L Pontes
Co-authored papers 2
Alfonso Monereo
Hospital Universitario de Getafe
Co-authored papers 2
Kris M White
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Jes??s Fort??n
Hospital Universitario Ramon y Cajal
Co-authored papers 2
Release 1.2